Kim Seon Young, Kim Ji-Eun, Kim Yoon Jun, Han Kyou-Sup, Kim Hyun Kyung
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
J Gastroenterol Hepatol. 2015 Apr;30(4):784-93. doi: 10.1111/jgh.12800.
Protein Z (PZ) is an anticoagulant that accelerates the inhibitory effect of PZ-dependent protease inhibitor (ZPI) on coagulation factor Xa. We assessed functional status of PZ system in 158 patients with liver cirrhosis and 59 healthy controls.
Plasma PZ and ZPI levels were measured by enzyme immunoassay. Thrombin generation assays (TGA) were performed with and without thrombomodulin (TM) or PZ, and the ratios were calculated by dividing TGA values with TM or PZ by values without TM or PZ.
PZ and ZPI levels were reduced and elevated in advanced cirrhosis, respectively. The lag time ratio-PZ was significantly higher in cirrhosis patients than controls and correlated with the model for end-stage liver disease score. The peak thrombin ratio-PZ and endogenous thrombin potential (ETP) ratio-PZ were significantly lower in cirrhosis patients than controls and correlated with the severity of liver cirrhosis. The peak thrombin ratio-PZ was dramatically reduced in advanced cirrhosis. Cirrhosis patients had a significantly higher ETP ratio-TM than the controls, although the ratio was not correlated with cirrhosis severity. The lag time ratio-PZ and peak time ratio-PZ were significantly correlated with the levels of all coagulation and anticoagulation factors. Interestingly, the lag time ratio-PZ and peak thrombin ratio-PZ were significantly associated with thrombotic events.
The anticoagulant role of PZ is insufficient in advanced stages of cirrhosis. Our newly developed functional assay for measuring the PZ system is expected to reflect the ongoing hypercoagulability of cirrhosis.
蛋白Z(PZ)是一种抗凝剂,可加速依赖PZ的蛋白酶抑制剂(ZPI)对凝血因子Xa的抑制作用。我们评估了158例肝硬化患者和59例健康对照者的PZ系统功能状态。
采用酶免疫分析法测定血浆PZ和ZPI水平。在有或无血栓调节蛋白(TM)或PZ的情况下进行凝血酶生成试验(TGA),并通过将有TM或PZ时的TGA值除以无TM或PZ时的TGA值来计算比值。
在晚期肝硬化中,PZ水平降低,ZPI水平升高。肝硬化患者的PZ滞后时间比值显著高于对照组,且与终末期肝病模型评分相关。肝硬化患者的PZ凝血酶峰值比值和内源性凝血酶潜力(ETP)比值显著低于对照组,且与肝硬化严重程度相关。晚期肝硬化患者的PZ凝血酶峰值比值显著降低。肝硬化患者的ETP-TM比值显著高于对照组,尽管该比值与肝硬化严重程度无关。PZ滞后时间比值和PZ峰值时间比值与所有凝血和抗凝因子水平显著相关。有趣的是,PZ滞后时间比值和PZ凝血酶峰值比值与血栓形成事件显著相关。
在肝硬化晚期,PZ的抗凝作用不足。我们新开发的用于测量PZ系统的功能测定法有望反映肝硬化患者持续存在的高凝状态。